Details for New Drug Application (NDA): 022058

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 022058 describes SUPPRELIN LA, which is a drug marketed by Endo Pharm and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the SUPPRELIN LA profile page.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

Summary for 022058

Tradename:	SUPPRELIN LA
Applicant:	Endo Pharm
Ingredient:	histrelin acetate
Patents:	1
Formulation / Manufacturing:	see details

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for 022058

Generic Entry Date for 022058^: See Plans and Pricing* Constraining patent/regulatory exclusivity: See Plans and Pricing Dosage: IMPLANT;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022058

Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

Suppliers and Packaging for NDA: 022058

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058	NDA	Endo Pharmaceuticals Inc.	67979-002	67979-002-01	1 VIAL, GLASS in 1 CARTON (67979-002-01) / 1 IMPLANT in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	IMPLANT;SUBCUTANEOUS			Strength	50MG
Approval Date:	May 3, 2007	TE:		RLD:	Yes
Patent:	See Plans and Pricing	Patent Expiration:	Jun 16, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

Expired US Patents for NDA 022058

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharm	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007	See Plans and Pricing	See Plans and Pricing
Endo Pharm	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.